SGEN Key Statistics, Chart & Performance
The current stock price of SGEN is 228.74 USD. In the past month the price increased by 6.91%. In the past year, price increased by 76.48%.
SGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.66 | 395.23B | ||
| AMGN | AMGEN INC | 15.04 | 177.18B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 151.02B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.73 | 117.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.17 | 81.24B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 797.29 | 53.72B | ||
| INSM | INSMED INC | N/A | 37.27B | ||
| NTRA | NATERA INC | N/A | 34.10B | ||
| BIIB | BIOGEN INC | 10.8 | 26.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.15 | 21.77B | ||
| INCY | INCYTE CORP | 16.63 | 20.97B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About SGEN
Company Profile
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 3,256 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. The company is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Company Info
SEAGEN INC
21823 30Th Drive Se, Suite
Bothell WASHINGTON 98021 US
CEO: Clay B. Siegall
Employees: 3256
Phone: 14255274000
SEAGEN INC / SGEN FAQ
What does SEAGEN INC do?
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 3,256 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. The company is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
What is the current price of SGEN stock?
The current stock price of SGEN is 228.74 USD. The price decreased by -0.07% in the last trading session.
Does SGEN stock pay dividends?
SGEN does not pay a dividend.
How is the ChartMill rating for SEAGEN INC?
SGEN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists SGEN stock?
SGEN stock is listed on the Nasdaq exchange.
Can you provide the market cap for SEAGEN INC?
SEAGEN INC (SGEN) has a market capitalization of 43.15B USD. This makes SGEN a Large Cap stock.
What is the next earnings date for SGEN stock?
SEAGEN INC (SGEN) will report earnings on 2024-02-13, after the market close.
SGEN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SGEN. When comparing the yearly performance of all stocks, SGEN is one of the better performing stocks in the market, outperforming 91.69% of all stocks.
SGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SGEN. While SGEN has a great health rating, there are worries on its profitability.
SGEN Financial Highlights
Over the last trailing twelve months SGEN reported a non-GAAP Earnings per Share(EPS) of -4.01. The EPS decreased by -16.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| Debt/Equity | 0 |
SGEN Forecast & Estimates
23 analysts have analysed SGEN and the average price target is 233.48 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 228.74.
For the next year, analysts expect an EPS growth of -28.74% and a revenue growth 28.4% for SGEN